首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Traditional Medicine to Modern Pharmacogenomics: AyurvedaPrakritiType and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability
【24h】

Traditional Medicine to Modern Pharmacogenomics: AyurvedaPrakritiType and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability

机译:传统药物到现代药物基因组学的研究:AyurvedaPrakritiType和CYP2C19基因多态性与代谢变异性相关

获取原文
           

摘要

Traditional Indian medicine—Ayurveda—classifies the human population into three major constituents orPrakritiknown asVata, PittaandKaphatypes. Earlier, we have demonstrated a proof of concept to support genetic basis forPrakriti. The descriptions in Ayurveda indicate that individuals withPitta Prakritiare fast metabolizers while those ofKapha Prakritiare slow metabolizers. We hypothesized that differentPrakritimay have different drug metabolism rates associated with drug metabolizing enzyme (DME) polymorphism. We didCYP2C19(Phase I DME) genotyping in 132 unrelated healthy subjects of either sex by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. We observed significant association betweenCYP2C19genotype and major classes ofPrakrititypes. The extensive metabolizer (EM) genotype (*1/*1, *1/*2, *1/*3) was found to be predominant inPitta Prakriti(91%). Genotype (*1/*3) specific for EM group was present only inPitta Prakriti.Poor metabolizer (PM) genotype (*2/*2, *2/*3, *3/*3) was highest (31%) inKapha Prakritiwhen compared withVata(12%) andPitta Prakriti(9%). Genotype (*2/*3) which is typical for PM group was significant inKapha Prakriti(odds ratio = 3.5,P=  .008).We observed interesting correlations betweenCYP2C19genotypes andPrakritiwith fast and slow metabolism being one of the major distinguishing and differentiating characteristics. These observations are likely to have significant impact on phenotype-genotype correlation, drug discovery, pharmacogenomics and personalized medicine.
机译:印度传统医学-阿育吠陀(Ayurveda)-将人类分为三大成分,即称为Vata,PittaandKaphatypes的Prakriti。之前,我们已经证明了支持Prakriti遗传基础的概念证明。阿育吠陀中的描述表明,具有Pitta Prakritiare代谢慢的人,而具有Katta Prakritiare代谢慢的人。我们假设不同的Prakritimay具有与药物代谢酶(DME)多态性相关的不同药物代谢率。我们通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对132位性别无关的健康个体进行了CYP2C19(Phase I DME)基因分型。我们观察到CYP2C19基因型与Prakrititypes的主要类别之间的显着关联。发现在Pitta Prakriti中占主导地位的代谢型(EM)基因型(* 1 / * 1,* 1 / * 2,* 1 / * 3)占主要比例(91%)。仅在Pitta Prakriti中存在针对EM组的基因型(* 1 / * 3),而代谢不良(PM)基因型(* 2 / * 2,* 2 / * 3,* 3 / * 3)在Kapha中最高(31%) Prakriti与Vata(12%)和Pitta Prakriti(9%)相比。在Kapha Prakriti中,PM组典型的基因型(* 2 / * 3)很显着(奇数比= 3.5,P = 0.008)。我们观察到CYP2C19基因型与Prakriti之间有趣的相关性,快慢代谢是主要的区别特征之一。这些观察结果可能对表型-基因型相关性,药物发现,药物基因组学和个性化医学产生重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号